Detalhe da pesquisa
1.
Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing.
Cell
; 182(5): 1232-1251.e22, 2020 09 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32822576
2.
Private Payer and Medicare Coverage Policies for Use of Circulating Tumor DNA Tests in Cancer Diagnostics and Treatment.
J Natl Compr Canc Netw
; 21(6): 609-616.e4, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37308126
3.
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.
Lancet Oncol
; 21(2): 271-282, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31838007
4.
Emerging Targeted Therapies for the Treatment of Non-small Cell Lung Cancer.
Curr Oncol Rep
; 21(3): 21, 2019 02 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-30806814
5.
Targeting MEK in non-small cell lung cancer.
Curr Probl Cancer
; 49: 101065, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38341356
6.
PERCEPTION predicts patient response and resistance to treatment using single-cell transcriptomics of their tumors.
Nat Cancer
; 2024 Apr 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-38637658
7.
Focal adhesion kinase-YAP signaling axis drives drug-tolerant persister cells and residual disease in lung cancer.
Nat Commun
; 15(1): 3741, 2024 May 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38702301
8.
The role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistance.
Nat Genet
; 56(1): 60-73, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-38049664
9.
Primary endpoints to assess the efficacy of novel therapeutic approaches in epidermal growth factor receptor-mutated, surgically resectable non-small cell lung cancer: A review.
Lung Cancer
; 177: 59-72, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36736076
10.
CD73 Inhibitor Oleclumab Plus Osimertinib in Previously Treated Patients With Advanced T790M-Negative EGFR-Mutated NSCLC: A Brief Report.
J Thorac Oncol
; 18(5): 650-656, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36641093
11.
Osimertinib in NSCLC With Atypical EGFR-Activating Mutations: A Retrospective Multicenter Study.
JTO Clin Res Rep
; 4(3): 100459, 2023 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-36879929
12.
MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or Chemotherapy.
J Thorac Oncol
; 18(7): 907-921, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-36842467
13.
Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC.
Cancer Discov
; 13(7): 1556-1571, 2023 07 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37068173
14.
Phase 1 Study of Ceritinib Combined With Trametinib in Patients With Advanced ALK- or ROS1-Positive NSCLC.
JTO Clin Res Rep
; 3(12): 100436, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36545322
15.
Changes in older adults' life space during lung cancer treatment: A mixed methods cohort study.
J Am Geriatr Soc
; 70(1): 136-149, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34611887
16.
Small-molecule targeted therapies induce dependence on DNA double-strand break repair in residual tumor cells.
Sci Transl Med
; 14(638): eabc7480, 2022 03 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-35353542
17.
Deficiency of the splicing factor RBM10 limits EGFR inhibitor response in EGFR-mutant lung cancer.
J Clin Invest
; 132(13)2022 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35579943
18.
AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung Cancer.
Cancer Discov
; 12(11): 2666-2683, 2022 11 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35895872
19.
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids.
J Vis Exp
; (177)2021 11 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-34866626
20.
Molecular Risk Stratification is Independent of EGFR Mutation Status in Identifying Early-Stage Non-Squamous Non-Small Cell Lung Cancer Patients at Risk for Recurrence and Likely to Benefit From Adjuvant Chemotherapy.
Clin Lung Cancer
; 22(6): 587-595, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34544620